申请人:Takeda Chemical Industries, Ltd.
公开号:US04804665A1
公开(公告)日:1989-02-14
Azaspiro compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, a hydrocarbon residue which may have a substituent, or an acyl group which may have a substituent; R.sub.3 represents hydrogen or a hydrocarbon residue which may have a substituent; each of X.sub.1 and X.sub.2 is oxygen or sulfur; Y represents oxygen, sulfur or a group of the formula: --N(R.sub.4)--, wherein R.sub.4 represents hydrogen or a lower alkyl group; m represents 0 or 1; n represents 0 or 1, and its salt are novel compounds, possess excellent brain function-improving action, and are of use as drugs for the prevention and therapy of senile dementia of Alzheimer type, vascular-type dementia and dementia derived from Alzheimer's disease, Pick's disease, Huntington's disease, Creutzfeldt-Jakob's disease, Parkinson's disease and spinocerebellar degeneration.
Azaspiro化合物的结构式为##STR1##其中R.sub.1和R.sub.2分别代表氢、可能具有取代基的碳氢残基,或者可能具有取代基的酰基;R.sub.3代表氢或者可能具有取代基的碳氢残基;X.sub.1和X.sub.2中的每一个代表氧或者硫;Y代表氧、硫或者具有以下结构的基团:--N(R.sub.4)--,其中R.sub.4代表氢或者较低的烷基基团;m代表0或1;n代表0或1,其盐是新颖的化合物,具有出色的改善脑功能的作用,并可用作预防和治疗老年性阿尔茨海默型痴呆、血管型痴呆以及源自阿尔茨海默病、皮克氏病、亨廷顿病、克雅茨菲尔德-雅各布病、帕金森病和脊髓小脑变性病的药物。